Cycle on Jul 12, 2026

I will start by listing existing threads and notes on this topic to understand what we are tracking and what open threads need resolution.

I will search for recent news on the FDA regulatory decision on gedatolisib for PIK3CA wild-type breast cancer, as its action date is expected around July 17, 2026. This is a highly relevant watch thread (`019f535e-c7d5-7317-939c-855999ccce9d`).

I will fetch the TechTimes article to see the specifics about the upcoming gedatolisib decision and confirm if anything else has occurred recently.

I will perform another quick search to see if any other active threads (like Replimune's RP1 or Capricor's deramiocel, or the H5N1 avian influenza in Australia) have updates. Let's search for "Australia H5N1 wild birds" or "Australia bird flu poultry" to see if there is any movement.

Let's fetch the article from Scimex or MSN about the Greater Crested Tern testing positive for H5 bird flu in South Australia, marking the first local/native seabird detection. This is extremely relevant to our ongoing watch thread `019f2f50-7f4d-7361-8f05-cdf170c2d727` ("Australia H5N1 transmission to poultry or local wildlife"). Let's fetch the Scimex page.

This is an incredibly important update on Australia's H5N1 avian influenza situation! The virus has officially jumped to a local, resident native seabird species—the Greater Crested Tern—in South Australia (confirmed on July 10, 2026), marking a key transition from purely migratory arrivals to potential local wildlife transmission. There is also a suspected infected fur seal in New South Wales mentioned by Prof. Raina MacIntyre. Now, let's search for some of the other active threads that have action dates in late July or around this time: 1. `019f1fe0-09fc-7028-9aca-1d1dd5636118` Amgen Tavneos FDA hearing submission extended deadline (July 29, 2026) 2. `019f061f-f34a-7079-a276-d216329928b2` FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy (July 29, 2026) 3. `019f0620-007b-7dab-87b4-0363a2496ea1` FDA advisory committee meeting and PDUFA date for Replimune's RP1 (August 2, 2026) 4. `019f1ab8-f9db-7f35-b537-f4db6a56efeb` FDA Expedited-IND Pilot Program RFI comment period (July 22, 2026) Let's do a search on "Capricor deramiocel FDA advisory committee July 2026" and "Replimune RP1 FDA advisory committee" to see if there are any updates or if the briefings have been posted. Also let's check "Amgen Tavneos FDA hearing submission".

Excellent, the Advisory Committee is still scheduled for July 29, 2026. No meeting materials are out yet (typically they are posted 2 days before the meeting). Let's search for "Amgen Tavneos FDA hearing submission" or "Amgen avacopan hearing". Tavneos is avacopan. Let's see if there are any recent updates.

Let's fetch the BioSpace article on Tavneos to see what has changed recently. We want to know if there's any new development or if the July 29 deadline is still the main focus.

This is a very clear and solid update on Amgen's Tavneos. The July 29 deadline for Amgen's hearing submission (with the Duke Clinical Research Institute's independent re-adjudication of ADVOCATE) is confirmed. Let's do a search on other active threads to see if there are updates: 1. "Vera Therapeutics ORIGIN 3 Q3 2026" or "atacicept IgAN 2026" 2. "Definium DT120 GAD 2026" 3. "MoonLake sonelokimab PsA IZAR-1 2026" 4. "Omeros narsoplimab TA-TMA EMA re-examination 2026" 5. "GondolaBio PORT-77 PATHWAY" 6. "Moderna mFlusiva PDUFA August 5 2026" Let's search for MoonLake's sonelokimab PsA IZAR-1 trial readout. This is expected "mid-2026" according to watch thread `019ef184-1ea4-72e1-a12e-ed934bbac64e`. Let's see if there are any results.

Let's expand the search for MoonLake and sonelokimab without "recent:true" or with a broader query. Let's search for "MoonLake sonelokimab psoriatic arthritis 2026".

Ah, the primary endpoint readout for IZAR-1 is expected by mid-2026, but it hasn't been announced yet. Let's keep a watch on that. Let's do a search on "Omeros narsoplimab TA-TMA EMA re-examination 2026" or "Omeros EMA narsoplimab". This watch thread (`019f0620-0add-7ac7-9db1-1ce428418522`) is about Omeros's request for re-examination of the negative CHMP opinion for narsoplimab in TA-TMA. Let's see if there are any recent updates.

Let's fetch the Seeking Alpha article or search more specifically about the June 26, 2026 press release by Omeros. Let's do a search for "Omeros June 26 2026 press release narsoplimab" to see what happened on June 26.

Let's fetch the June 26, 2026 press release by Omeros regarding the European Marketing Authorization Application (MAA) for narsoplimab in TA-TMA. This is from Yahoo Finance or Omeros's investor relations. Let's fetch the Yahoo Finance link.

The Omeros update is excellent and directly addresses watch thread `019f0620-0add-7ac7-9db1-1ce428418522`. On June 26, 2026, Omeros announced that the EMA's CHMP adopted a negative opinion on the MAA for narsoplimab in TA-TMA. Omeros intends to request re-examination of the CHMP opinion and seek a review by an Ad Hoc Expert Group (AHEG). Because this watch thread is still active (it is monitoring the request for re-examination, the convening of the AHEG, and the final decision), I can record an event for this watch thread to note that the *negative opinion* has landed, and the re-examination has been requested, but keep the watch open (`resolves: false`) until the final re-examination outcome is decided. Wait, let's look at the watch thread description: "Monitor Omeros's request for re-examination of the negative CHMP opinion for narsoplimab in TA-TMA, the convening of the Ad Hoc Expert Group (AHEG), and the final decision." Since the negative opinion *just* happened on June 26, 2026, and they officially announced they *intend* to request re-examination, let's record a progress event on it. Let's do a search on other active threads to see if they have updates: - "Moderna mFlusiva PDUFA August 5 2026" or "mRNA-1010 FDA" - "Vera Therapeutics ORIGIN 3" or "atacicept IgAN Q3 2026" - "Replimune RP1 FDA advisory committee meeting" (PDUFA August 2, 2026) Let's search for "Replimune RP1 FDA advisory committee 2026" to see if there is any scheduled date or meeting details. This is watch thread `019f0620-007b-7dab-87b4-0363a2496ea1`.

Let's do a search specifically for "Replimune RP1 BLA resubmission" or "Replimune RP1 advisory committee date". We see: "FDA Accepts Third RP1 BLA Resubmission for Advanced Melanoma. By Kaitlyn Bader, Assistant Managing Editor. June 26th 2026. The FDA has accepted Replimune's..." Let's search for that.

Ah! The search budget is spent. That is perfectly fine, we have some incredible, high-quality, and highly relevant updates from the searches we did. Let's review the updates we found: 1. **Australia H5N1 Avian Influenza**: On July 10, 2026, Australia confirmed its first case of highly pathogenic H5N1 bird flu in a local, resident native seabird—a Greater Crested Tern—found in Robe, South Australia. This marks a critical transition from purely migratory birds (like Brown Skuas and Giant Petrels) to native local wildlife, raising the risk of local ecological establishment and spillover to domestic poultry. This directly updates watch thread `019f2f50-7f4d-7361-8f05-cdf170c2d727`. 2. **Omeros's Narsoplimab (YARTEMLEA) in TA-TMA**: On June 26, 2026, Omeros announced that the EMA's CHMP adopted a negative opinion on the Marketing Authorization Application (MAA) for narsoplimab in TA-TMA. Omeros plans to request a formal re-examination and seek review by an Ad Hoc Expert Group (AHEG). This directly updates watch thread `019f0620-0add-7ac7-9db1-1ce428418522`. 3. **Amgen's Tavneos (avacopan) Hearing Submission**: Amgen is actively preparing its hearing submission to the FDA due by July 29, 2026, defending the drug's safety and efficacy following the NEJM retraction of the pivotal ADVOCATE trial. The submission will include independent re-adjudication results conducted by the Duke Clinical Research Institute (DCRI). This updates watch thread `019f1fe0-09fc-7028-9aca-1d1dd5636118`. 4. **Celcuity's Gedatolisib FDA Action Date**: The FDA's upcoming decision on Celcuity's gedatolisib for PIK3CA wild-type HR+/HER2- advanced breast cancer is expected by July 17, 2026. This updates watch thread `019f535e-c7d5-7317-939c-855999ccce9d`. Let's write notes for these key developments. Wait, do we have existing notes to update, or do we create new ones? Let's check `read_notes` first to see if there are any existing notes we should update. Let's call `read_notes` to see what notes are already in the system.

This is extremely helpful! Let's see what notes we should update or write new ones for: 1. **Australia H5N1**: There is an existing note `australia-h5n1-wildlife-transmission` (updated on July 10, 2026) titled "Australia H5N1 Escalation: First Case Confirmed in Local Native Seabird". Wait, the current time is `2026-07-12 22:40`. This note was updated on July 10, 2026 (just 2 days ago). Let's review if there are any new details to add. The Scimex article is dated July 10, 2026. This note already exists. Let's see if we should refine it or if it is already fully covered. Let's check the content of `australia-h5n1-wildlife-transmission` first by writing a note or reading it. Wait, we can't read a single note's body directly from the tool output unless we update it or fetch it, but we can see the title and preview. 2. **Omeros's Narsoplimab (YARTEMLEA) in TA-TMA**: There is `omeros-narsoplimab-chmp-negative-opinion-ta-tma` and `omeros-narsoplimab-ema-rejection-regulatory-divide`. Wait, the June 26, 2026 announcement is already in those notes. 3. **Amgen's Tavneos (avacopan)**: There are several notes: `amgen-tavneos-fda-hearing-nejm-retraction`, `amgen-tavneos-chmp-revocation-data-integrity`, `amgen-tavneos-eu-revocation-us-fda-extension`, `nejm-retracts-tavneos-advocate-trial-paper-amgen-fda-ema-withdrawal`, `amgen-tavneos-fda-scrutiny-withdrawal-dispute`. The June 29 NEJM retraction is covered. 4. **Celcuity's Gedatolisib**: There is NO note for gedatolisib yet! Let's write a new note for gedatolisib with a fresh slug `celcuity-gedatolisib-fda-pdufa-breast-cancer`. This is a major, highly significant upcoming oncology regulatory action expected by July 17, 2026. Wait, let's look at the watch threads to see if we can resolve any or record events. The watch thread `019f535e-c7d5-7317-939c-855999ccce9d` is: "Monitor the FDA's regulatory decision on gedatolisib for PIK3CA wild-type breast cancer, with an expected action date of July 17, 2026." Since the date is July 17, 2026, and today is July 12, 2026, the decision has NOT happened yet. We don't resolve it yet, but we will write a finding note summarizing the upcoming catalyst, preclinical/clinical mechanism, and Phase 3 trial data to establish the baseline for the future cycle that will resolve it. Let's write a note on gedatolisib. Let's make sure it contains: - Name and link to the source (the TechTimes article, the JCO publication). - 1-2 representative verbatim quotes, each kept with its link. - Interpret what it means. Let's write the note body for slug `celcuity-gedatolisib-fda-pdufa-breast-cancer`. First, let's draft it carefully.

Now let's check if we want to record any events or watches. We have: 1. Watch `019f2f50-7f4d-7361-8f05-cdf170c2d727`: "Australia H5N1 transmission to poultry or local wildlife" - Trigger: "Fires when Australia confirms the transmission of H5N1 to commercial poultry flocks, native land birds, or local marine mammal colonies." - The confirmation of H5N1 in a Greater Crested Tern (a local resident/native seabird, not a Southern Ocean migratory bird) on July 10, 2026, marks the first transmission of H5N1 to a native local bird species in Australia. - Let's record an event on this watch thread to show that it has fired. Since it's an `ongoing` watch (monitoring spread to poultry or wildlife), we will set `resolves: false` (keep it open for future cycles to track further spread, e.g., to poultry or land mammals). Let's call `record_event` on `019f2f50-7f4d-7361-8f05-cdf170c2d727`.

Now let's check watch `019f0620-add7-ac7-9db1-1ce428418522`: "EMA re-examination outcome on Omeros's narsoplimab in TA-TMA" - This thread is monitoring Omeros's request for re-examination of the negative CHMP opinion. - On June 26, 2026, the negative CHMP opinion was officially adopted. Omeros announced its intention to request re-examination and seek review by an Ad Hoc Expert Group (AHEG). - Let's record an event on this thread to track this progression, keeping the watch open (`resolves: false`) until the re-examination and AHEG review are completed. Let's record this event.

Ah! Let's check the thread ID for Omeros's narsoplimab. From `list_threads`: `id: "019f0620-0add-7ac7-9db1-1ce428418522"` Wait, in my tool call, I wrote: `019f0620-add7-ac7-9db1-1ce428418522`. That was a typo. Let's call it with the correct ID: `019f0620-0add-7ac7-9db1-1ce428418522`.

Excellent. The event has been successfully recorded. Let's call `finish_cycle` to complete this research cycle. Since we wrote a substantive finding on gedatolisib, we do not need a `no_findings_reason`. Let's finish the cycle.

I have successfully completed the research cycle. ### Summary of Actions & Key Findings: 1. **Gedatolisib (Celcuity) FDA Action Baseline Established:** * **Finding Created:** Created a new note (`[[celcuity-gedatolisib-fda-pdufa-breast-cancer]]`) detailing the upcoming July 17, 2026 PDUFA action date for Celcuity's **gedatolisib** in PIK3CA wild-type HR+/HER2- advanced breast cancer. * **Efficacy & Safety Profile:** Highlighted the Phase 3 VIKTORIA-1 trial results where the triplet regimen achieved a median PFS of **9.3 months** versus **2.0 months** for fulvestrant monotherapy (76% risk reduction; HR 0.24, P < .0001). Also noted the mechanistic advantage of dual PI3K/mTOR inhibition in wild-type tumors and a significantly cleaner hyperglycemia profile (2.3% Grade 3) compared to selective PI3Kα inhibitors. 2. **Australia H5N1 Avian Influenza Escalation:** * **Event Recorded:** Registered an event on the ongoing watch thread (`019f2f50-7f4d-7361-8f05-cdf170c2d727`). * **Key Update:** On July 10, 2026, Australia confirmed its first case of highly pathogenic H5N1 bird flu in a **local native seabird** (a Greater Crested Tern) in Robe, South Australia. This marks a critical transition from purely sub-Antarctic migratory species (like Skuas and Giant Petrels) to local resident wildlife, significantly elevating the risk of local ecological establishment and spillover to domestic poultry. 3. **Omeros's Narsoplimab (YARTEMLEA) EMA Review Progression:** * **Event Recorded:** Registered a progress event on the watch thread (`019f0620-0add-7ac7-9db1-1ce428418522`). * **Key Update:** On June 26, 2026, the EMA's CHMP officially adopted a negative opinion on the Marketing Authorization Application (MAA) for narsoplimab in TA-TMA. Omeros announced its intent to request a formal re-examination and seek review from an independent Ad Hoc Expert Group (AHEG) to align with the FDA's December 2025 approval. 4. **Amgen's Tavneos (avacopan) FDA Hearing Submission Status:** * **Status Confirmed:** Confirmed Amgen's timeline for submitting independent re-adjudication results of the ADVOCATE trial (conducted by the Duke Clinical Research Institute) as part of its FDA hearing submission due by **July 29, 2026**.